Drug details:
Molecular formula: C₁₉H₁₄F₂N₂O₅

Standard name: 5-[[3-[(2,4-difluorophenoxy)methyl]-4-methoxyphenyl]methylidene]-1,3-diazinane-2,4,6-trione

Synonyms:

5-[[3-[(2,4-difluorophenoxy)methyl]-4-methoxyphenyl]methylidene]-1,3-diazinane-2,4,6-trione 5-{3-[(2,4-difluorophenoxy)methyl]-4-methoxybenzylidene}pyrimidine-2,4,6(1H,3H,5H)-trione

Curated SMILES: COC1=C(C=C(C=C1)C=C2C(=O)NC(=O)NC2=O)COC3=C(C=C(C=C3)F)F

Evidence for compound's anti-virulence activity:

Clostridium
Related VF: theta-toxin/PFO (Perfringolysin O)
Target: PfoA
Drug effect: Blocks Perfringolysin O (PFO)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PFO-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.

Streptococcus
Related VF: Pneumolysin
Target: Ply
Drug effect: Blocks Pneumolysin (PLY)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PLY-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.